Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients. 

Initial data on Amgen’s AMG 193 give some Tango investors a headache.

The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.

Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.

But Repare and Black Diamond still have rebuilding to do.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.